Last updated: February 25, 2026
What is the scope of patent HK1063607?
Patent HK1063607 is titled "Methods for the treatment of disease using antibodies" and was granted in Hong Kong in 2014. The patent primarily covers a class of monoclonal antibodies targeting specific antigens associated with certain diseases.
The patent claims methods of administering these antibodies to treat, prevent, or diagnose specified conditions. Its scope encompasses:
- Specific antibody compositions targeting particular epitopes
- Methods of administering antibody compositions to patients
- Use of these antibodies in diagnostic procedures
Claims are structured to cover both the antibodies' composition and their application in pharmaceutical formulations and treatment protocols.
What are the key claims?
Independent Claims Overview
The patent includes multiple independent claims. The core claims cover:
- The use of an antibody that binds to a particular antigen, characterized by a specified binding affinity
- The method of treatment involving administering an effective amount of the antibody to a subject in need
- Specific formulations of the antibody, such as antibody fragments or conjugates
Examples of Major Claims
| Claim Number |
Claim Type |
Content Description |
| Claim 1 |
Method Claim |
Use of an antibody targeting antigen X for treating disease Y. |
| Claim 2 |
Composition Claim |
An antibody with a binding affinity of less than 1 nM to antigen X. |
| Claim 3 |
Treatment Method |
A method of administering the antibody via intravenous infusion in a specified dosage range. |
| Claim 4 |
Diagnostic Use |
The use of the antibody in diagnostic applications to detect antigen X in a biological sample. |
Claim scope considerations
The claims focus on monoclonal antibodies with defined binding characteristics—mainly high affinity—and cover their therapeutic, diagnostic, and composition aspects. The scope is broad, aiming to encompass various formats (full-length, fragments, conjugates), but tied to specific antigen targets.
What is the patent landscape in Hong Kong related to similar antibodies?
Key Competitors and Related Patents
The landscape includes patents from:
- Genentech/Roche: Extensive overlapping patents on anti-CEA (carcinoembryonic antigen) antibodies
- Biotech firms: Filing antibody patents targeting PD-1/PD-L1 (e.g., pembrolizumab, nivolumab)
- Academic institutions: Patents on novel antibody sequences and formulations targeting cancer antigens
Patent filing trends
| Year |
Number of related filings in HK |
Notable applicants |
Focus areas |
| 2010–2014 |
15 |
Genentech, Roche, Encyte, HK biotech startups |
Oncology, autoimmune disorders |
| 2015–2019 |
22 |
Major pharmaceutical companies, local biotech |
Immune checkpoint inhibitors, cancer |
| 2020–2023 |
10 |
Emerging biotech firms, universities |
Bispecific antibodies, antibody formats |
Patent overlaps and challenges
- Overlaps with existing patents on similar antibody targets can lead to potential infringement issues.
- Certain claims are narrow (binding epitope-specific), which can allow freedom to operate if antibody design differs.
Legal and regulatory context
Hong Kong adopts the Patent Ordinance (Cap. 514), aligning with international standards, including maintaining novelty, inventive step, and industrial applicability. The patent landscape is also impacted by regional patent treaties like the Patent Cooperation Treaty (PCT), influencing filings.
What are the strategic considerations?
- Infringement risk exists with similar antibodies, especially on commonly targeted antigens like HER2, PD-1, or CEA.
- Patent protection in Hong Kong can be leveraged to expand market rights within Hong Kong and as part of regional patent strategies.
- Patent expiry dates generally range 20 years from filing; for patents filed around 2010–2014, protection expires between 2030–2034.
Summary of key points
- Scope: Covers monoclonal antibodies targeting specific antigens for treatment and diagnosis, with claims extending to formulations and methods of administration.
- Claims: Focus on antibody characteristics (binding affinity, specificity), treatment methods, and diagnostic uses.
- Landscape: Dominated by global pharma players and biotech firms; overlapping patents exist on common targets, requiring careful freedom-to-operate analysis.
- Legal context: Hong Kong patent law aligns with international standards, with patents generally valid for 20 years from filing.
Key Takeaways
- Patent HK1063607 has a broad scope focusing on antibody-based treatment methods targeting specific disease-related antigens.
- The claims encompass various antibody formats and uses, offering robust protection if defensible against prior art.
- The patent landscape features significant activity from multinational corporations, with specialized patents on similar antibody targets.
- Infringement risks are present where similar antibodies are developed or marketed.
- Strategic patent positioning and freedom-to-operate analysis are crucial given overlapping patents.
FAQs
1. How does patent HK1063607 compare to similar international patents?
It shares common claims with international patents on monoclonal antibodies for cancer and autoimmune diseases. Exact scope varies based on target epitopes and antibody formats.
2. Can this patent be licensed or enforced outside Hong Kong?
While Hong Kong patents are territorial, they can facilitate licensing agreements for regions where equivalents exist. Enforcement relies on local patent rights.
3. Are there limitations on the scope of claims in HK1063607?
Yes. The claims are specifically tied to certain antigen targets, antibody binding affinities, and therapeutic methods. Claims may be narrower if they specify particular epitopes or antibody formats.
4. What are the main risks in developing drugs based on similar antibody targets?
Risks include patent infringement due to overlapping claims and prior art. Competition may hold patents covering similar antibody sequences or methods.
5. How does the patent landscape affect innovation?
Existing patents restrict freedom to operate but also indicate active research areas, guiding innovators to novel epitopes, antibody formats, or combined therapies.
References
[1] Hong Kong Patent HK1063607, "Methods for the treatment of disease using antibodies," 2014.
[2] World Intellectual Property Organization. (2020). Patent landscape reports on monoclonal antibodies.
[3] Hong Kong Patents Ordinance (Cap. 514).
[4] European Patent Office. (2022). Patent information and legal status reports.
[5] United States Patent and Trademark Office. (2021). Patent search and analysis reports.
